Big pharma, Partnering, Pharma

Bayer and X-Chem in cardiovascular drug discovery program pact

Posted on 18 December 2014

Tags: , ,

X-Chem has licensed a second drug discovery program to Bayer Pharma pursuant to the multi-target collaboration the companies established in July 2012.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

 

The latest program comprises several series of small molecule compounds against a cardiovascular drug target.

X-Chem will receive an upfront license fee in addition to payments based on the achievement of defined pre-clinical, clinical and sales milestones, as well as royalties.

The financial terms of the license are not disclosed and are commensurate with terms X-Chem has established in its collaborations with other major pharmaceutical companies.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Report:   Top 50 Big Pharma Partnering and M&A Deal Trends

Report:   Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

Print Friendly, PDF & Email

Leave a Reply